There is mounting evidence supporting the multi-potency anti-cancer activities of Cardamonin via modulating various signaling pathways, transcriptional factors, cytokines and enzymes, such as mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2 [52]. The gene discussed is NFKB1; the disease is cancer.